1. Home
  2. Directory
  3. Indiana
  4. Greendale
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1164050779

EMILY LUNN
Prescription History 1164050779
Internal Medicine - Endocrinology, Diabetes & Metabolism in Greendale, IN

NPI Status: Active since March 30, 2020

Contact Information

1640 FLOSSIE DR
GREENDALE, IN
ZIP 47025
Phone: (859) 655-8910
Fax: (859) 655-8911

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for EMILY LUNN, an active Endocrinology, Diabetes & Metabolism specialist practicing in Greendale, IN. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 78 documented patient claims. Among these therapy options, the most frequently utilized medication is Ozempic, which accounts for 21 claims alone.

Medication Index

L
M
O
T
No matching medications currently found on file.

Linzess

Generic Formulation: LinaclotideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
IN State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills40.3
Peer Average Days Supply1,203
Conservative Utilization

This provider writes prescriptions for this formulation 40.7% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,816.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$551.04

State Avg Cost Per Claim

$771.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

See also Warning section. Linaclotide is used to treat certain types of bowel problems (irritable bowel syndrome with constipation, chronic idiopathic constipation). It works by increasing fluid in your intestines and helping speed up movement of food through the gut. Linaclotide may improve stool texture and lessen symptoms such as bloating, abdominal pain/discomfort, straining, and feelings of incomplete bowel movements.

Lisinopril

Generic Formulation: LisinoprilSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 15
30-Day Fills 23.2
Days Supply 694
IN State Average Benchmarks
Peer Average Claims131.0
Peer Average 30-Day Fills317.7
Peer Average Days Supply9,360
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 88.5% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $204.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.60

State Avg Cost Per Claim

$6.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.

Therapeutic Applications

Lisinopril is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat heart failure and to improve survival after a heart attack. Lisinopril belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.

Meloxicam

Generic Formulation: MeloxicamSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.2
Days Supply 387
IN State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills102.8
Peer Average Days Supply3,027
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.4% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $205.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.78

State Avg Cost Per Claim

$6.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.

Therapeutic Applications

Meloxicam is used to help relieve moderate to severe pain. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation. This effect helps to decrease swelling or pain.

Ozempic

Generic Formulation: SemaglutideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 21
30-Day Fills 26.3
Days Supply 756
IN State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills59.4
Peer Average Days Supply1,734
Conservative Utilization

This provider writes prescriptions for this formulation 46.2% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,551.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,073.87

State Avg Cost Per Claim

$1,432.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Semaglutide is also used in people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Semaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and decreasing the amount of sugar your liver makes. If you use insulin, semaglutide is not a substitute for insulin treatment.

Trulicity

Generic Formulation: DulaglutideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 13
30-Day Fills 18.4
Days Supply 532
IN State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills64.6
Peer Average Days Supply1,840
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.5% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,345.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,488.12

State Avg Cost Per Claim

$1,381.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dulaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. This medication is also used to lessen the risk of a major cardiovascular event (such as heart attack or stroke) in people who already have, or are at high risk for heart/blood vessel disease. Dulaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and by decreasing the amount of sugar your liver makes. Dulaglutide is not a substitute for insulin if you need insulin treatment.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like EMILY LUNN provides transparency into local medical care patterns within Greendale, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Endocrinology, Diabetes & Metabolism** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.